1. Eligibility and Cost-Utility Analysis of Dapagliflozin in Patients with Heart Failure Across the Whole Spectrum of Ejection Fraction in South Korea.
- Author
-
Kim, Eui-Soon, Park, Sun-Kyeong, Cho, Daniel Sung-ho, Youn, Jong-Chan, Lee, Hye Sun, Lee, Hae-Young, Cho, Hyun-Jai, Choi, Jin-Oh, Jeon, Eun-Seok, Lee, Sang Eun, Kim, Min-Seok, Kim, Jae-Joong, Hwang, Kyung-Kuk, Cho, Myeong-Chan, Chae, Shung Chull, Kang, Seok-Min, Park, Jin Joo, Choi, Dong-Ju, Yoo, Byung-Su, and Cho, Jae Yeong
- Subjects
STATISTICAL models ,VENTRICULAR ejection fraction ,COST effectiveness ,RESEARCH funding ,DAPAGLIFLOZIN ,HEART failure ,COST benefit analysis ,DESCRIPTIVE statistics ,ELIGIBILITY (Social aspects) ,MEDICAL care costs ,COMORBIDITY - Abstract
Background: The DAPA-HF and DELIVER trials demonstrated the clinical benefits of dapagliflozin in heart failure (HF) patients across the entire ejection fraction (EF) spectrum. However, further investigation is needed for the real-world application of dapagliflozin in HF patients. This study examines the proportion of real-world HF patients eligible for dapagliflozin and evaluates the cost-effectiveness of adding dapagliflozin to current HF therapy. Methods: Data from the nationwide prospective registry, the Korean Acute Heart Failure (KorAHF) registry, were used to determine dapagliflozin eligibility based on the enrollment criteria of the DAPA-HF/DELIVER trials. A cost-utility analysis was conducted using a Markov model to assess the cost-effectiveness of dapagliflozin by comparing it to the standard of care. Results: Out of 5178 KorAHF patients, 48.7% met the enrollment criteria of the DAPA-HF/DELIVER trials, while 89.5% met the label criteria (US Food and Drug Administration, European Medicines Agency, and Korean Ministry of Food and Drug Safety). Eligibility was highest among HF patients with preserved EF (55.3% vs. HF with mildly reduced EF and HF with reduced EF 46.4%). Dapagliflozin proved to be cost-effective, with an incremental cost-effectiveness ratio (ICER) of 4557 US dollar (US$) per quality-adjusted life year, which falls below the US$18,182 willingness-to-pay threshold. The cost-effectiveness benefit was more pronounced in patients with a left ventricular EF (LVEF) ≤ 40% (ICER US$3279 for LVEF ≤ 40% vs. US$8383 for LVEF > 40%). Conclusions: Discrepancies in dapagliflozin eligibility were observed between real-world data and clinical trial results. The addition of dapagliflozin to HF therapy proved to be highly cost-effective across the entire EF spectrum. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF